Search Results

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.

- Company listed in Research and Markets’ announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - “U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"- -Report supports Company’s regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential for rapid market adoption and significant market share -

Aleta Biotherapeutics, a clinical stage, immuno-oncology company with a CAR T-Cell Engager platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, announce the first patient was dosed in a Phase 1/2 clinical trial.

Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc., a leading precision oncology company, announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment.

Britannia selling its UK lab and testing business to a private UK-based acquiror for total enterprise value of up to £24.2 million (CAD$43.6 million) Initial consideration of £18.7 million (CAD$33.7 million) payable in cash on closing Additional consideration of up to £5.5 million (CAD$9.9 million) payable contingent on achieving certain EBITDA targets at March 2025 and December 2025. After the disposition Britannia will be debt free with assets that consist of significant cash reserves, and shares in Britannia Mining Solutions and Cosmetics Lab